CP7 Control Synthetic Peptide
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-31231
Key Product Details
Source
Synthetic
Conjugate
Unconjugated
Applications
Functional Assay
Product Specifications
Description
A peptide to CP7 Control.
Amino Acid Sequence: RNTISGNIYSARRRRRRRRR
Inhibitor Content: CP7, Control Peptide: 1 mg (lyophilized) RNTISGNIYSARRRRRRRRR (Control sequence: RNTISGNIYSA). Molecular weight: 2601
Inhibitor Family: TLR
Inhibitor Target: TLR4
Inhibitor Type: Inhibitor Peptide Set
Purity
>95%, by HPLC.
Protein / Peptide Type
Synthetic Peptide
Formulation, Preparation and Storage
NBP2-31231
| Preparation Method | Preparation of 5 mM CP7 Stock Solution Note: Bring the peptide to room temperature and quick spin the tubes before opening the caps. CP7: A final volume of 76 ul will make a 5 mM stock solution. Add 76 ul sterile H20 to the tube of peptide. Carefully pipet to ensure all of the peptide is dissolved. The stock solution may be diluted further to make working solutions. Dilute according to the needs for your assay. For example dilute 5 mM stock solutions 1:10 in sterile 1X PBS or cell culture media to make 500 uM working solutions. Working solutions should be made fresh daily and not stored. |
| Concentration | Lyoph |
| Reconstitution | Please contact technical support for detailed reconstitution instructions. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Store at -20C. Avoid freeze-thaw cycles. |
Background: CP7 Control
CP7 is an inert control peptide. The control consists of an 11 amino acid (RNTISGNIYSA) inert sequence also linked to a 9R homopolymer delivery sequence. The 9R sequence efficiently delivers the peptides into cells. CP7 is designed to be a negative control peptide for inhibitory assays.
We note that this inhibitor is the first viral inhibitory peptide identified that is specific for a particular TLR pathway. Inhibition of TLR4 within the context of the overall TLR signaling network is illustrated in Figure 2. VIPER should be useful for elucidating new mechanisms and molecular interactions involved in TLR4 signaling, and may also have potential for leading to the development of a new class of novel therapeutics that perturb TLR4 signaling by targeting Mal and TRAM TIR domains. The identification of additional short virally derived peptides that perturb TLR signaling is sure to open a new era in knowledge about how viruses specifically interact with host immune systems.
Additional CP7 Control Products
Product Documents for CP7 Control Synthetic Peptide
Product Specific Notices for CP7 Control Synthetic Peptide
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...